Quetiapine (Seroquel) and Lactation
Quetiapine is compatible with breastfeeding, as it transfers into breast milk in very low amounts with minimal infant exposure and no consistent adverse effects reported. 1
Evidence from FDA Drug Label
The FDA label for Seroquel explicitly states that limited published data report quetiapine presence in human breast milk at a relative infant dose of <1% of the maternal weight-adjusted dosage 1. Critically, there are no consistent adverse events reported in infants exposed to quetiapine through breast milk 1. The label emphasizes weighing the developmental and health benefits of breastfeeding against the mother's clinical need for quetiapine and any potential adverse effects on the infant.
Supporting Research Evidence
Multiple pharmacokinetic studies confirm the FDA's position:
A 2018 study of 9 lactating women taking quetiapine (mean dose 41 mg/day) found mean milk concentrations of only 5.7 ng/mL, with infant exposure calculated at just 0.16% of the weight-adjusted maternal dose 2. This is well below the generally accepted 10% threshold for concern.
A 2007 study demonstrated an even lower relative infant dose of 0.09% of the maternal weight-adjusted dose, with the infant plasma concentration only 6% of the maternal level 3. The milk-to-plasma ratio was 0.29, indicating poor transfer into breast milk.
A 2023 naturalistic study found quetiapine showed low milk/serum-penetration ratios and low concentration-by-dose ratios in breastmilk 4, with no significant developmental differences in exposed children during the first 12 months.
A 2016 systematic review of second-generation antipsychotics during lactation concluded that quetiapine has low relative infant dose values, with antipsychotic levels undetectable in most exposed infants' plasma 5.
Clinical Implications
Quetiapine does not impact milk production directly, though the FDA notes that as a D2 antagonist, it may theoretically increase prolactin levels 1. However, this mechanism would actually support rather than inhibit lactation.
Important Caveats:
- Monitor the infant for sedation, feeding difficulties, or developmental concerns, though these have been rarely reported 3, 6
- The data primarily reflect short-term usage; long-term effects require more study 5
- Most safety data comes from low to moderate doses; higher doses warrant increased vigilance
- Individual risk-benefit assessment remains essential, particularly when quetiapine is used in combination with other psychotropics 6, 7
Bottom line: Breastfeeding can continue normally while taking quetiapine, with routine infant monitoring for any signs of sedation or feeding problems.